The figure represents 87.6 percent of all the inhabitants of the island (a little more than 11 million 180 thousand) who have the initial injection of Soberana 02, Soberana Plus designed by the Finlay Vaccine Institute, or Abdala, from the Center for Genetic Engineering and Biotechnology.
Data from the Ministry of Public Health (Minsap) indicate that a total of 6,983,983,98 Cubans have the complete immunization plan, that is to say, three doses and also include those convalescing from the disease, to whom a single dose of Soberana Plus is administered.
These numbers represent 71.3 percent of the vaccine-eligible population, that is, those without any health problem and with all the possibilities to receive the national products, and 62.4 percent of all Cubans.
According to the latest report published by the health entity, there are eight million 780 thousand 716 (78.5 percent) with a second dose applied and six million 699 thousand 378 (59.9 percent) with a third dose.
In Cuba, a total of 25 million 275,700 doses of these products have been applied up to the 22nd of this month.
The Caribbean nation thus ranks first in Latin America in anti-Covid-19 immunization, followed by Chile and Uruguay.
In addition to having three anti-Covid-19 vaccines authorized for use in emergencies, Cuba has two other candidates: Soberana 01 and Mambisa, the latter one of the 10 vaccines in the world designed for nasal administration.
The country was the first in the world to initiate a massive immunization campaign against Covid-19 in children from two to 18 years of age with the immunogens Soberana 02 and Soberana Plus, in a scheme of three doses separated in 28 days.
Recently, Cuba’s Finlay Vaccine Institute reported that more than one million children and adolescents received the two doses of Soberana 02 and by November the vaccination of children is expected to be completed when they receive the booster injection of Soberana Plus.